Inflection Biosciences to Present at Annual BioPharm America International Partnering Conference

(15 Sep 2014)

Dublin, Ireland, September 15, 2014 – Inflection Biosciences Ltd, a private company focused on the development of targeted small molecule treatments for cancer, today announced that the Company has been selected to present at the Next Generation Track at BioPharm America 2014 in Boston, September 22-24, 2014.

Inflection Biosciences’ presentation will be given by Darren Cunningham, Chief Executive Officer, on Wednesday September 24 at 10.50 a.m. EDT in the Suffolk Room of the Boston Marriott Copley Place.

 

About BioPharm America

BioPharm America is where biotech industry partnerships get started. Meet face-to-face with biotech and pharma executives from around the world to identify and enter strategic relationships. Equipped with partneringONE®, BioPharm America is the only event in North America based on the same reputable formula as EBD Group's acclaimed European events BIO-Europe® and BIO-Europe Spring®.

 

About Inflection Biosciences

Inflection Biosciences Ltd, based in Dublin and London, is developing small molecule therapeutics for the treatment of cancer. The company's pipeline of highly innovative cancer treatments were licensed from the Spanish National Cancer Research Centre (CNIO). The pipeline comprises a unique dual mechanism pan-PIM/PI3 kinase inhibitor program and a pan-PIM kinase inhibitor program, both in preclinical development. Data generated to date suggests potential application in a range of haematological malignancies and treatment resistant solid tumours. For more information please visit the Company’s website at www.inflectionbio.com

 

Image

Search

Search - Use spaces to separate your keywords
Inflection Biosciences. Suite 15, Anglesea House Carysfort Avenue, Blackrock,  Co. Dublin.  

 Company registration no. 509046.

© 2020 Inflection Biosciences.   Web Design by Webtrade